Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection
9m
·
Oncology Times - OncTimes Talk
·
Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the findings of a study presented at the 2024 European Breast Cancer Conference in Amsterdam, The Netherlands.
Annemiek van Hemert, a Medical Doctor and PhD candidate at the Surgical Oncology Department of the Antoni van Leeuwenhoek-Netherlands Cancer Institute in Amsterdam, The Netherlands, reported her findings from a study using the MARI protocol (marking axillary lymph nodes with radioactive iodine seeds) that predicts cancer outcomes. The protocol was developed at the AVL Hospital in 2014 and is now being used in several Dutch hospitals.
After her session at the Milan conference, van Hemert talked with OncTimesTalk correspondent Peter Goodwin about the clinical implications of her group’s findings.
The episode Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection from the podcast Oncology Times - OncTimes Talk has a duration of
9:42. It was first published
More episodes from Oncology Times - OncTimes Talk
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting.
After giving his talk in San Diego, lead author Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology and Director of the Center of Excellence for Multiple Myeloma at the Icahn School of Medicine at Mount Sinai in New York, met up with OncTimesTalk correspondent Peter Goodwin to discuss the therapeutic progress the drug offers.
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection
An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells.
At the AACR Annual Meeting 2024 in San Diego, Peter Goodwin talked with Ajay Goel, PhD, AGAF, senior author of the study and Chair of the Molecular Diagnostics and Experimental Therapeutics in the Beckman Research Institute at City of Hope in Los Angeles.
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers
Designed with the help of artificial intelligence to recognize multiple genetic features of each patient’s tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in some patients.
At the AACR Annual Meeting 2024, Olivier Lantz, MD, PhD, Head of the Clinical Immunology Laboratory at the Institut Curie Hospital in Paris, reported data using a “neoantigen-based vaccine” specifically designed to recognize multiple genetic features unique to each patient’s tumor. During the conference, Lantz called into the OncTimesTalk studio to tell Peter Goodwin about the clinical options that could develop from such highly personalized vaccines.
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery
Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral method of breast reconstruction using titanized mesh pockets after their surgery for breast cancer.
At the 14th European Breast Cancer Conference in Milan, Stefan Paepke, MD, from the Interdisciplinary Breast Centre at the Technical University of Munich in Germany, said the technique prevents the unnatural breast mobility patients can experience after reconstruction, sometimes called jumping breasts.
After reporting his group’s 24-month follow-up data from the prospective international mesh-supported, pre-pectoral breast reconstruction trial (PRO-Pocket Trial) at the conference, he discussed the findings with Peter Goodwin.
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed
The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable efficacy for the two boost regimens, with less toxicity among patients receiving the low boost.
The trial findings were reported by Sophie Bosma, MD, PhD, Radiation Oncologist from The Netherlands Cancer Institute in Amsterdam at the 14th European Breast Cancer Conference held in Milan. After her talk, she discussed the findings with Peter Goodwin.